Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimensDaniel Podzamczer, Antonio Rivero, Mar Masiá et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 10
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)Daniel Podzamczer, Santiago Moreno, Rafael Micán et al.|Open Forum Infectious Diseases|2021Cited by 7